Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.67 |
| ▸ | NPY2R | P49146 | 1/20 | 0.67 |
| ▸ | NPY4R | P50391 | 1/20 | 0.67 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.67 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.66 |
| ▸ | GLP1R | P43220 | 11/20 | 0.65 |
| ▸ | GIPR | P48546 | 6/20 | 0.65 |
| ▸ | GCGR | P47871 | 3/20 | 0.65 |
| ▸ | CALCA | P06881 | 2/20 | 0.64 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29972944 | 0.96 | NPY1R (0.69) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30973903 | 0.92 | NPY1R (0.66) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29625326 | 0.90 | NPY1R (0.72) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30824296 | 0.90 | NPY2R (0.74) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30041162 | 0.90 | CALCA (0.64) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29972984 | 0.90 | NPY1R (0.65) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29843747 | 0.89 | NPY1R (0.73) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL31182780 | 0.89 | C5AR1 (0.66) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL30906424 | 0.89 | NPY2R (0.70) | NPY1RNPY2RNPY4RNPY5RCXCR4 | |
| SCHEMBL29351718 | 0.88 | NPY1R (0.71) | NPY1RNPY2RNPY4RNPY5RCXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 120 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022153-A1 | GLUCOSE-RESPONSIVE INSULIN ANALOGS AND METHODS OF USE THEREOF | AmideBio LLC (US) | 2026-01-22 | — | — | US | claimed |
| CN-119751552-A | Semiglutide intermediate, preparation method thereof and synthesis method of Semiglutide | 深圳翰宇药业股份有限公司 | 2025-04-04 | — | — | CN | claimed |
| WO-2025038031-A1 | ENGINEERED MITOCHONDRION | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2025-02-20 | — | — | WO | claimed |
| CN-114832155-B | Preparation and application of biomineralization-based hydroxyapatite with controllable hydrophilicity and hydrophobicity | 大连理工大学 | 2022-11-15 | — | — | CN | claimed |
| WO-2022236018-A1 | M13 PHAGE BASED GENE THERAPY PLATFORM | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-11-10 | — | — | WO | claimed |
| CN-114832155-A | Preparation and application of biomineralization-based hydroxyapatite with controllable hydrophilicity and hydrophobicity | 大连理工大学 | 2022-08-02 | — | — | CN | claimed |
| US-20260092887-A1 | SENSORS USING POLYMERIC MATRICES | US GOV AIR FORCE (US) | 2026-04-02 | — | — | US | disclosed |
| EP-4689072-A1 | GENETICALLY MODIFIED CELLS INTO WHICH A NUCLEIC ACID ENCODING A STEFIN A PROTEIN VARIANTS SPECIFICALLY BINDING TO TNFR2 OR A FUSION PROTEIN COMPRISING THE SAME HAS BEEN INTRODUCED, AND USES THEREOF | AffyXell Therapeutics Co., Ltd. (KR) | 2026-02-11 | — | — | EP | disclosed |
| US-12534533-B2 | Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications | OSE IMMUNOTHERAPEUTICS (FR) | 2026-01-27 | — | — | US | disclosed |
| US-20260022343-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | AFFYXELL THERAPEUTICS CO LTD (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20260022160-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | AFFYXELL THERAPEUTICS CO LTD (KR) | 2026-01-22 | — | — | US | disclosed |
| US-20260022153-A1 | GLUCOSE-RESPONSIVE INSULIN ANALOGS AND METHODS OF USE THEREOF | AmideBio LLC (US) | 2026-01-22 | — | — | US | disclosed |
| US-20250346634-A1 | CYCLIC PEPTIDES FOR TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND MUTATIONS THEREOF FOR DRUG DELIVERY | Ariel Scientific Innovations Ltd. (IL) | 2025-11-13 | — | — | US | disclosed |
| CN-111494601-B | Rumen-bypass enteric-soluble antibacterial peptide particles and preparation method thereof | 安杰利(重庆)生物科技有限公司 | 2022-04-22 | — | — | CN | disclosed |
| WO-2022076947-A1 | PEPTIDE INHIBITORS OF GLIOMA-ASSOCIATED ONCOGENE DERIVED FROM THE COILED-COIL DIMERIZATION DOMAIN OF KIF7 | THE GENERAL HOSPITAL CORPORATION (US) | 2022-04-14 | — | — | WO | disclosed |
| WO-2022067445-A1 | BIOACTIVE COLLAGEN PEPTIDES, METHOD OF PRODUCTION THEREOF, AND USE THEREOF | CORPORATION GENACOL CANADA INC. (CA) | 2022-04-07 | — | — | WO | disclosed |
| US-11285219-B2 | Peptide-oligourea hybrid compounds | UREKA SARL (FR) | 2022-03-29 | — | — | US | disclosed |
| US-11274131-B2 | IgM-mediated receptor clustering and cell modulation | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2022-03-15 | — | — | US | disclosed |
| WO-2022036466-A1 | NANOFORMULATION FOR TREATING AND/OR PREVENTING WOUNDS OR ULCERS THAT ARE INFECTED OR HAVE CRITICAL COLONISATION, WHICH INCLUDES COPPER NANOPARTICLES AND COLLAGEN-DERIVED PEPTIDES | UNIVERSIDAD MAYOR (CL) | 2022-02-24 | — | — | WO | disclosed |
| CN-114025786-A | Compositions and methods for protecting epithelial and barrier integrity | 欧耐柯萨斯医疗有限公司 | 2022-02-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022153-A1 | GLUCOSE-RESPONSIVE INSULIN ANALOGS AND METHODS OF USE THEREOF | IAPP, INSR, GLP1R | NPY1R 38/4885NPY2R 65/4885NPY4R 59/4885 |
| US-20250346634-A1 | CYCLIC PEPTIDES FOR TARGETING EPIDERMAL GROWTH FACTOR RECEPTOR AND MUTATIONS THEREOF FOR DRUG DELIVERY | EGFR, ERBB3, ERBB2 | NPY1R 302/4885NPY2R 481/4885NPY4R 524/4885 |
| US-12534533-B2 | Anti-chemokine like receptor 1 humanized antibodies and their therapeutic applications | CMKLR1, ACKR3, CMKLR2 | NPY1R 349/4885NPY2R 616/4885NPY4R 687/4885 |
| US-20260092887-A1 | SENSORS USING POLYMERIC MATRICES | GRIA3, GAP43, GRIA4 | NPY1R 306/4885NPY2R 291/4885NPY4R 276/4885 |
| US-11285219-B2 | Peptide-oligourea hybrid compounds | IAPP, NGLY1, NPPA | NPY1R 588/4885NPY2R 960/4885NPY4R 642/4885 |
| US-20260022160-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | HAVCR2, VCAM1, DBNL | NPY1R 3369/4885NPY2R 1726/4885NPY4R 2025/4885 |
| US-20260022343-A1 | GENETICALLY MODIFIED CELLS COMPRISING A NUCLEIC ACID ENCODING A CD40L BINDING AGENT AND USES THEREOF | VSIR, NECTIN4, VSIG8 | NPY1R 3493/4885NPY2R 2118/4885NPY4R 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.